Natasa Przulj at the Barcelona Supercomputing Center is developing an AI framework that fuses multi-omic data to improve precision medicine. The framework uses graph-regularized non-negative matrix tri-factorization (NMTF) and network science algorithms for patient stratification, biomarker prediction, and drug repurposing. It is applied to diseases like cancer, Covid-19, and Parkinson's. Why it matters: This research can enable more personalized and effective treatments by leveraging complex biological data to understand disease mechanisms and tailor therapies.
KAUST and Oxford Nanopore Technologies have signed an MoU to collaborate on multi-omics research, building on previous work such as the NanoRanger technique developed by KAUST's Mo Li. KAUST will gain early access to Oxford Nanopore’s sequencing technology, while Oxford Nanopore will access KAUST's Core Labs. Why it matters: This partnership enhances KAUST's research capabilities in areas like rare diseases and desert agriculture, and provides Oxford Nanopore with a launchpad to engage with Saudi Arabia's research community.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
A senior lecturer at the University of New South Wales discussed the use of AI to improve early prognosis and personalized treatment plans for neurodegenerative diseases, cardiovascular imaging and multiomics. The lecture highlighted the potential of AI algorithms to detect subtle changes at early stages through advanced multiomics techniques and medical imaging analysis. The speaker has expertise in analyzing medical images and has collaborated with medical professionals to develop AI tools for diagnosis of cancer, neurodegenerative disease, and heart disease. Why it matters: AI-driven prognosis and treatment planning promises earlier intervention and improved outcomes for challenging diseases in the region.
Eran Segal from Weizmann Institute of Science presented The Human Phenotype Project, a large-scale prospective cohort with over 10,000 participants. The project aims to identify novel molecular markers and develop prediction models for disease onset using deep profiling. The profiling includes medical history, lifestyle, blood tests, and molecular profiling of the transcriptome, genetics, microbiome, metabolome and immune system. Why it matters: Such projects demonstrate the growing focus on personalized medicine in the region, utilizing advanced AI and machine learning techniques for disease prevention and treatment.
This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.
KAUST's Computational Bioscience Research Center (CBRC) held a Research Conference on Big Data Analyses in Evolutionary Biology. The conference focused on the impact of large "omics" datasets on evolutionary biology, requiring big data approaches for analysis. Researchers discussed how computer science can contribute to biology and vice versa. Why it matters: Such interdisciplinary events at KAUST can foster innovation at the intersection of computational science and biology, advancing research in both fields.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.